Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE)

Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE)

A study involving molecular profiling that started at Princess Margaret in 2012 (IMPACT), quickly expanded to include other regional hospitals (COMPACT).
 
This study analyzed the individual mutations in cancer tissue of 3,000 cancer patients with advanced solid tumours. The purpose was to give oncologists more information to direct their patients to new treatments and clinical trials when standard treatments were no longer effective.
 
Interest in this work spurred the creation of a third study known as OCTANE, launched in 2016, that involves four other hospitals across southern and eastern Ontario. It is building upon the knowledge gained from IMPACT and COMPACT. The goal of OCTANE is to enable province-wide data sharing.